Jounce Therapeutics Inc Stock
-
Your prediction
Pros and Cons of Jounce Therapeutics Inc in the next few years
Pros
Cons
Performance of Jounce Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics Inc | - | - | - | - | - | - | - |
| Immunic Inc. | -0.690% | 1.139% | -5.949% | -19.018% | -19.301% | -90.399% | - |
| NanoViricides Inc. | 1.960% | -3.774% | 0.990% | -10.526% | 7.937% | -70.605% | -77.232% |
| Ocuphire Pharma Inc. | 1.540% | -13.780% | -26.963% | -70.785% | -49.410% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the available financial data provided, it appears that Jounce, operating under the US symbol JNCE, displays a combination of strengths and weaknesses in its financial performance. As a company in the competitive Biotechnology & Medical Research industry, it has experienced fluctuations in key financial metrics. While some aspects of the company's financials are cause for optimism, others might be of concern to investors or stakeholders.
Improved Net Income: In the most recent quarter, the company's net income increased significantly to $50,959,000, as compared to a net loss of $50,919,000 in the previous year. This positive shift in net income can be a good sign for investors and stakeholders.
Increased Cash Flow from Operating Activities: The cash flow from operating activities in the latest quarter was $59,234,000, a significant improvement from the previous year's cash flow position. This demonstrates that the company's operations generated a substantial amount of cash, which can be used for reinvestment, debt repayment, or distribution to shareholders.
